<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.irs.gov/efile" returnVersion="2020v4.2">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2022-05-16T10:23:50-05:00</ReturnTs>
    <TaxPeriodEndDt>2021-06-30</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>135565207</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>KPMG LLP</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>550 S HOPE ST STE 1500</AddressLine1Txt>
        <CityNm>LOS ANGELES</CityNm>
        <StateAbbreviationCd>CA</StateAbbreviationCd>
        <ZIPCd>90071</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990</ReturnTypeCd>
    <TaxPeriodBeginDt>2020-07-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>311611837</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>MARC LUSTGARTEN PANCREATIC CANCER</BusinessNameLine1Txt>
        <BusinessNameLine2Txt>FOUNDATION</BusinessNameLine2Txt>
      </BusinessName>
      <BusinessNameControlTxt>MARC</BusinessNameControlTxt>
      <PhoneNum>5167371550</PhoneNum>
      <USAddress>
        <AddressLine1Txt>415 CROSSWAYS PARK DRIVE SUITE D</AddressLine1Txt>
        <CityNm>WOODBURY</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>11797</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>LINDA TANTAWI</PersonNm>
      <PersonTitleTxt>CEO</PersonTitleTxt>
      <PhoneNum>5167371550</PhoneNum>
      <SignatureDt>2022-05-16</SignatureDt>
      <DiscussWithPaidPreparerInd>1</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <SigningOfficerGrp>
      <PersonFullName>
        <PersonFirstNm>LINDA</PersonFirstNm>
        <PersonLastNm>TANTAWI</PersonLastNm>
      </PersonFullName>
      <SSN>999009999</SSN>
    </SigningOfficerGrp>
    <PreparerPersonGrp>
      <PreparerPersonNm>PABLO CORA</PreparerPersonNm>
      <PTIN>P01721022</PTIN>
      <PhoneNum>2139724000</PhoneNum>
      <PreparationDt>2022-05-13</PreparationDt>
    </PreparerPersonGrp>
    <AdditionalFilerInformation>
      <TrustedCustomerGrp>
        <TrustedCustomerCd>0</TrustedCustomerCd>
        <AuthenticationAssuranceLevelCd>AAL1</AuthenticationAssuranceLevelCd>
        <IdentityAssuranceLevelCd>IAL1</IdentityAssuranceLevelCd>
      </TrustedCustomerGrp>
    </AdditionalFilerInformation>
    <TaxYr>2020</TaxYr>
    <BuildTS>2022-09-23 18:48:47Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="10">
    <IRS990 documentId="RetDoc1038000001" referenceDocumentId="RetDoc1044400001">
      <DoingBusinessAsName>
        <BusinessNameLine1Txt>CURE PANCREATIC CANCER LUSTGARTEN FO</BusinessNameLine1Txt>
      </DoingBusinessAsName>
      <PrincipalOfficerNm>LINDA TANTAWI</PrincipalOfficerNm>
      <USAddress>
        <AddressLine1Txt>415 CROSSWAYS PARK DR SUITE D</AddressLine1Txt>
        <CityNm>WOODBURY</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>11797</ZIPCd>
      </USAddress>
      <GrossReceiptsAmt>95900067</GrossReceiptsAmt>
      <GroupReturnForAffiliatesInd>0</GroupReturnForAffiliatesInd>
      <Organization501c3Ind>X</Organization501c3Ind>
      <WebsiteAddressTxt>WWW.LUSTGARTEN.ORG</WebsiteAddressTxt>
      <TypeOfOrganizationCorpInd>X</TypeOfOrganizationCorpInd>
      <FormationYr>1998</FormationYr>
      <LegalDomicileStateCd>NY</LegalDomicileStateCd>
      <ActivityOrMissionDesc>THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. THE FOUNDATION'S MISSION IS TO CURE PANCREATIC CANCER BY FUNDING SCIENTIFIC AND CLINICAL RESEARCH RELATED TO THE DIAGNOSIS, TREATMENT AND PREVENTION OF PANCREATIC CANCER; PROVIDING RESEARCH INFORMATION AND CLINICAL SUPPORT SERVICES TO PATIENTS, CAREGIVERS AND INDIVIDUALS AT HIGH RISK; AND INCREASING PUBLIC AWARENESS AND HOPE FOR THOSE DEALING WITH THIS DISEASE. SINCE ITS INCEPTION, THE LUSTGARTEN FOUNDATION HAS DIRECTED MORE THAN $225 MILLION TO RESEARCH AND HAS ASSEMBLED THE BEST SCIENTIFIC MINDS WITH THE HOPE THAT ONE DAY, A CURE CAN BE FOUND.</ActivityOrMissionDesc>
      <VotingMembersGoverningBodyCnt>15</VotingMembersGoverningBodyCnt>
      <VotingMembersIndependentCnt>14</VotingMembersIndependentCnt>
      <TotalEmployeeCnt>25</TotalEmployeeCnt>
      <TotalVolunteersCnt>150</TotalVolunteersCnt>
      <TotalGrossUBIAmt>0</TotalGrossUBIAmt>
      <NetUnrelatedBusTxblIncmAmt>0</NetUnrelatedBusTxblIncmAmt>
      <PYContributionsGrantsAmt>13046433</PYContributionsGrantsAmt>
      <CYContributionsGrantsAmt>15661608</CYContributionsGrantsAmt>
      <PYProgramServiceRevenueAmt>0</PYProgramServiceRevenueAmt>
      <CYProgramServiceRevenueAmt>0</CYProgramServiceRevenueAmt>
      <PYInvestmentIncomeAmt>2409428</PYInvestmentIncomeAmt>
      <CYInvestmentIncomeAmt>7644241</CYInvestmentIncomeAmt>
      <PYOtherRevenueAmt>-489227</PYOtherRevenueAmt>
      <CYOtherRevenueAmt>1161984</CYOtherRevenueAmt>
      <PYTotalRevenueAmt>14966634</PYTotalRevenueAmt>
      <CYTotalRevenueAmt>24467833</CYTotalRevenueAmt>
      <PYGrantsAndSimilarPaidAmt>18894873</PYGrantsAndSimilarPaidAmt>
      <CYGrantsAndSimilarPaidAmt>15742900</CYGrantsAndSimilarPaidAmt>
      <PYBenefitsPaidToMembersAmt>0</PYBenefitsPaidToMembersAmt>
      <CYBenefitsPaidToMembersAmt>0</CYBenefitsPaidToMembersAmt>
      <PYSalariesCompEmpBnftPaidAmt>2890871</PYSalariesCompEmpBnftPaidAmt>
      <CYSalariesCompEmpBnftPaidAmt>3030185</CYSalariesCompEmpBnftPaidAmt>
      <PYTotalProfFndrsngExpnsAmt>385093</PYTotalProfFndrsngExpnsAmt>
      <CYTotalProfFndrsngExpnsAmt>697612</CYTotalProfFndrsngExpnsAmt>
      <CYTotalFundraisingExpenseAmt>2427517</CYTotalFundraisingExpenseAmt>
      <PYOtherExpensesAmt>2691944</PYOtherExpensesAmt>
      <CYOtherExpensesAmt>2255332</CYOtherExpensesAmt>
      <PYTotalExpensesAmt>24862781</PYTotalExpensesAmt>
      <CYTotalExpensesAmt>21726029</CYTotalExpensesAmt>
      <PYRevenuesLessExpensesAmt>-9896147</PYRevenuesLessExpensesAmt>
      <CYRevenuesLessExpensesAmt>2741804</CYRevenuesLessExpensesAmt>
      <TotalAssetsBOYAmt>90551380</TotalAssetsBOYAmt>
      <TotalAssetsEOYAmt>96561632</TotalAssetsEOYAmt>
      <TotalLiabilitiesBOYAmt>9811073</TotalLiabilitiesBOYAmt>
      <TotalLiabilitiesEOYAmt>3614475</TotalLiabilitiesEOYAmt>
      <NetAssetsOrFundBalancesBOYAmt>80740307</NetAssetsOrFundBalancesBOYAmt>
      <NetAssetsOrFundBalancesEOYAmt>92947157</NetAssetsOrFundBalancesEOYAmt>
      <InfoInScheduleOPartIIIInd>X</InfoInScheduleOPartIIIInd>
      <MissionDesc>THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. SEE SCHEDULE O.THE FOUNDATION'S MISSION IS TO CURE PANCREATIC CANCER BY FUNDING SCIENTIFIC AND CLINICAL RESEARCH RELATED TO THE DIAGNOSIS, TREATMENT AND PREVENTION OF PANCREATIC CANCER; PROVIDING RESEARCH INFORMATION AND CLINICAL SUPPORT SERVICES TO PATIENTS, CAREGIVERS AND INDIVIDUALS AT HIGH RISK; AND INCREASING PUBLIC AWARENESS AND HOPE FOR THOSE DEALING WITH THIS DISEASE.</MissionDesc>
      <SignificantNewProgramSrvcInd>0</SignificantNewProgramSrvcInd>
      <SignificantChangeInd>0</SignificantChangeInd>
      <ExpenseAmt>16556918</ExpenseAmt>
      <GrantAmt>15742900</GrantAmt>
      <Desc>RESEARCH PROGRAM: THE FOUNDATION'S MISSION IS TO CURE PANCREATIC CANCER. TO ADVANCE PROGRESS TOWARD THIS GOAL, THE FOUNDATION COMMITTED AN ADDITIONAL $24 MILLION TO RESEARCH DURING FY2021, BRINGING THE CUMULATIVE TOTAL INVESTED THROUGH JUNE 2021 TO $225 MILLION. SEE SCHEDULE O.</Desc>
      <ProgSrvcAccomActy2Grp>
        <ExpenseAmt>1004578</ExpenseAmt>
        <Desc>PUBLIC EDUCATION AND INFORMATION PROGRAM: THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. THE FOUNDATION'S MISSION IS TO CURE PANCREATIC CANCER BY FUNDING SCIENTIFIC AND CLINICAL RESEARCH RELATED TO THE DIAGNOSIS, TREATMENT AND PREVENTION OF PANCREATIC CANCER; PROVIDING RESEARCH INFORMATION AND CLINICAL SUPPORT SERVICES TO PATIENTS, CAREGIVERS AND INDIVIDUALS AT HIGH RISK; AND INCREASING PUBLIC AWARENESS AND HOPE FOR THOSE DEALING WITH THIS DISEASE. SEE SCHEDULE O.PUBLIC EDUCATION AND INFORMATION PROGRAMTHE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. THE FOUNDATION'S MISSION IS TO CURE PANCREATIC CANCER BY FUNDING SCIENTIFIC AND CLINICAL RESEARCH RELATED TO THE DIAGNOSIS, TREATMENT AND PREVENTION OF PANCREATIC CANCER; PROVIDING RESEARCH INFORMATION AND CLINICAL SUPPORT SERVICES TO PATIENTS, CAREGIVERS AND INDIVIDUALS AT HIGH RISK; AND INCREASING PUBLIC AWARENESS AND HOPE FOR THOSE DEALING WITH THIS DISEASE.THE LUSTGARTEN FOUNDATION CREATED, PRINTED AND DISTRIBUTED MATERIALS TO UPDATE PATIENTS, CAREGIVERS, SURVIVORS, DONORS, VOLUNTEERS, WALK AND EVENT LEADERS AND CORPORATE SPONSORS ON RESEARCH DEVELOPMENTS, FOUNDATION MILESTONES AND WALKS/EVENTS. MATERIALS INCLUDED: - LUSTGARTENLIVE! SERIES OF RESEARCH-FOCUSED, INTERACTIVE WEBINARS - PROGRESS &amp; PROMISE NEWSLETTERS - ANNUAL REPORT - MONTHLY E-NEWSLETTER WITH VIDEO INTRODUCTION - RESEARCH MILESTONES UPDATE - INCREASED FOCUS ON VIDEO, INCLUDING A VIRTUAL TOUR OF THE LUSTGARTEN LAB AT COLD SPRING HARBOR LABORATORY - PRE-PACKAGED ARTICLE FOR PUBLICATION IN COMMUNITY NEWSPAPERS NATIONWIDE WITH ACCOMPANYING RADIO PUBLIC SERVICE ANNOUNCEMENT - TELEVISION PUBLIC SERVICE ANNOUNCEMENT FOCUSING ON THE FOUNDATION'S COMMITMENT TO RESEARCH - PANCREATIC CANCER COLLECTIVE RADIO AND DIGITAL PUBLIC SERVICE ANNOUNCEMENTS FOCUSED ON INCREASING DIVERSITY IN CLINICAL TRIALS.WE ALSO CONTINUE DISTRIBUTING OUR UNDERSTANDING PANCREATIC CANCER: A GUIDE FOR PATIENTS &amp; CAREGIVERS HANDBOOK, CONTAINING INFORMATION ON NAVIGATING A PANCREATIC CANCER DIAGNOSIS AND TREATMENT. THE BOOK AND MANY OF THE MATERIALS NOTED ABOVE ARE ACCESSIBLE AT WWW.LUSTGARTEN.ORG.</Desc>
      </ProgSrvcAccomActy2Grp>
      <ProgSrvcAccomActy3Grp>
        <ExpenseAmt>159898</ExpenseAmt>
        <Desc>PROFESSIONAL EDUCATION PROGRAM: PROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SENIOR LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH SCIENTISTS, DIRECTORS OF THE DEDICATED LABORATORIES AND COLLABORATING ORGANIZATIONS AS WELL AS ATTENDING/PRESENTING VIRTUALLY AT SCIENTIFIC MEETINGS FOR ORGANIZATIONS INCLUDING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) AND STAND UP TO CANCER. SEE SCHEDULE O.PROFESSIONAL EDUCATION PROGRAMPROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SENIOR LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH SCIENTISTS, DIRECTORS OF THE DEDICATED LABORATORIES AND COLLABORATING ORGANIZATIONS AS WELL AS ATTENDING/PRESENTING VIRTUALLY AT SCIENTIFIC MEETINGS FOR ORGANIZATIONS INCLUDING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) AND STAND UP TO CANCER. THE FOUNDATION SERVED AS A LEAD SPONSOR FOR THE AACR SPECIAL MEETING ON PANCREATIC CANCER HELD VIA ZOOM IN SEPTEMBER 2021. THE FOUNDATION HELD ITS ANNUAL SCIENTIFIC MEETING FOR THE SCIENTIFIC ADVISORY BOARD AND SELECT RESEARCHERS VIA ZOOM IN NOVEMBER 2021 AS WELL. THESE MEETINGS HELP FOSTER COLLABORATION AND A BETTER UNDERSTANDING OF GLOBAL DEVELOPMENTS IN PANCREATIC CANCER RESEARCH AND PROGRESS/TRENDS TO HELP SHAPE THE FOUNDATION'S ANNUAL RESEARCH PROGRAM AND LONG-TERM STRATEGIC GOALS.</Desc>
      </ProgSrvcAccomActy3Grp>
      <TotalProgramServiceExpensesAmt>17721394</TotalProgramServiceExpensesAmt>
      <DescribedInSection501c3Ind referenceDocumentId="RetDoc1039100001">1</DescribedInSection501c3Ind>
      <ScheduleBRequiredInd referenceDocumentId="RetDoc1234500001">1</ScheduleBRequiredInd>
      <PoliticalCampaignActyInd>0</PoliticalCampaignActyInd>
      <LobbyingActivitiesInd>0</LobbyingActivitiesInd>
      <SubjectToProxyTaxInd>0</SubjectToProxyTaxInd>
      <DonorAdvisedFundInd referenceDocumentId="RetDoc1040000001">0</DonorAdvisedFundInd>
      <ConservationEasementsInd referenceDocumentId="RetDoc1040000001">0</ConservationEasementsInd>
      <CollectionsOfArtInd referenceDocumentId="RetDoc1040000001">0</CollectionsOfArtInd>
      <CreditCounselingInd referenceDocumentId="RetDoc1040000001">0</CreditCounselingInd>
      <DonorRstrOrQuasiEndowmentsInd>0</DonorRstrOrQuasiEndowmentsInd>
      <ReportLandBuildingEquipmentInd referenceDocumentId="RetDoc1040000001">1</ReportLandBuildingEquipmentInd>
      <ReportInvestmentsOtherSecInd referenceDocumentId="RetDoc1040000001">0</ReportInvestmentsOtherSecInd>
      <ReportProgramRelatedInvstInd referenceDocumentId="RetDoc1040000001">0</ReportProgramRelatedInvstInd>
      <ReportOtherAssetsInd referenceDocumentId="RetDoc1040000001">0</ReportOtherAssetsInd>
      <ReportOtherLiabilitiesInd referenceDocumentId="RetDoc1040000001">1</ReportOtherLiabilitiesInd>
      <IncludeFIN48FootnoteInd referenceDocumentId="RetDoc1040000001">1</IncludeFIN48FootnoteInd>
      <IndependentAuditFinclStmtInd referenceDocumentId="RetDoc1040000001">1</IndependentAuditFinclStmtInd>
      <ConsolidatedAuditFinclStmtInd referenceDocumentId="RetDoc1040000001">0</ConsolidatedAuditFinclStmtInd>
      <SchoolOperatingInd>0</SchoolOperatingInd>
      <ForeignOfficeInd>0</ForeignOfficeInd>
      <ForeignActivitiesInd referenceDocumentId="RetDoc1040500001">1</ForeignActivitiesInd>
      <MoreThan5000KToOrgInd referenceDocumentId="RetDoc1040500001">1</MoreThan5000KToOrgInd>
      <MoreThan5000KToIndividualsInd referenceDocumentId="RetDoc1040500001">0</MoreThan5000KToIndividualsInd>
      <ProfessionalFundraisingInd referenceDocumentId="RetDoc1041200001">1</ProfessionalFundraisingInd>
      <FundraisingActivitiesInd referenceDocumentId="RetDoc1041200001">1</FundraisingActivitiesInd>
      <GamingActivitiesInd referenceDocumentId="RetDoc1041200001">0</GamingActivitiesInd>
      <OperateHospitalInd>0</OperateHospitalInd>
      <GrantsToOrganizationsInd referenceDocumentId="RetDoc1041900001">1</GrantsToOrganizationsInd>
      <GrantsToIndividualsInd referenceDocumentId="RetDoc1041900001">0</GrantsToIndividualsInd>
      <ScheduleJRequiredInd referenceDocumentId="RetDoc1042400001">1</ScheduleJRequiredInd>
      <TaxExemptBondsInd>0</TaxExemptBondsInd>
      <EngagedInExcessBenefitTransInd>0</EngagedInExcessBenefitTransInd>
      <PYExcessBenefitTransInd>0</PYExcessBenefitTransInd>
      <LoanOutstandingInd>0</LoanOutstandingInd>
      <GrantToRelatedPersonInd>0</GrantToRelatedPersonInd>
      <BusinessRlnWithOrgMemInd>0</BusinessRlnWithOrgMemInd>
      <BusinessRlnWithFamMemInd>0</BusinessRlnWithFamMemInd>
      <BusinessRlnWith35CtrlEntInd>0</BusinessRlnWith35CtrlEntInd>
      <DeductibleNonCashContriInd referenceDocumentId="RetDoc1042900001">1</DeductibleNonCashContriInd>
      <DeductibleArtContributionInd referenceDocumentId="RetDoc1042900001">0</DeductibleArtContributionInd>
      <TerminateOperationsInd>0</TerminateOperationsInd>
      <PartialLiquidationInd>0</PartialLiquidationInd>
      <DisregardedEntityInd>0</DisregardedEntityInd>
      <RelatedEntityInd>0</RelatedEntityInd>
      <RelatedOrganizationCtrlEntInd>0</RelatedOrganizationCtrlEntInd>
      <TrnsfrExmptNonChrtblRltdOrgInd>0</TrnsfrExmptNonChrtblRltdOrgInd>
      <ActivitiesConductedPrtshpInd>0</ActivitiesConductedPrtshpInd>
      <ScheduleORequiredInd>1</ScheduleORequiredInd>
      <IRPDocumentCnt>29</IRPDocumentCnt>
      <IRPDocumentW2GCnt>0</IRPDocumentW2GCnt>
      <BackupWthldComplianceInd>1</BackupWthldComplianceInd>
      <EmployeeCnt>25</EmployeeCnt>
      <EmploymentTaxReturnsFiledInd>1</EmploymentTaxReturnsFiledInd>
      <UnrelatedBusIncmOverLimitInd>0</UnrelatedBusIncmOverLimitInd>
      <ForeignFinancialAccountInd>0</ForeignFinancialAccountInd>
      <ProhibitedTaxShelterTransInd>0</ProhibitedTaxShelterTransInd>
      <TaxablePartyNotificationInd>0</TaxablePartyNotificationInd>
      <NondeductibleContributionsInd>0</NondeductibleContributionsInd>
      <QuidProQuoContributionsInd>1</QuidProQuoContributionsInd>
      <QuidProQuoContriDisclInd>1</QuidProQuoContriDisclInd>
      <Form8282PropertyDisposedOfInd>0</Form8282PropertyDisposedOfInd>
      <RcvFndsToPayPrsnlBnftCntrctInd>0</RcvFndsToPayPrsnlBnftCntrctInd>
      <PayPremiumsPrsnlBnftCntrctInd>0</PayPremiumsPrsnlBnftCntrctInd>
      <IndoorTanningServicesInd>0</IndoorTanningServicesInd>
      <SubjToTaxRmnrtnExPrchtPymtInd>0</SubjToTaxRmnrtnExPrchtPymtInd>
      <SubjectToExcsTaxNetInvstIncInd>0</SubjectToExcsTaxNetInvstIncInd>
      <InfoInScheduleOPartVIInd>X</InfoInScheduleOPartVIInd>
      <GoverningBodyVotingMembersCnt>15</GoverningBodyVotingMembersCnt>
      <IndependentVotingMemberCnt>14</IndependentVotingMemberCnt>
      <FamilyOrBusinessRlnInd>1</FamilyOrBusinessRlnInd>
      <DelegationOfMgmtDutiesInd>0</DelegationOfMgmtDutiesInd>
      <ChangeToOrgDocumentsInd>0</ChangeToOrgDocumentsInd>
      <MaterialDiversionOrMisuseInd>0</MaterialDiversionOrMisuseInd>
      <MembersOrStockholdersInd>0</MembersOrStockholdersInd>
      <ElectionOfBoardMembersInd>0</ElectionOfBoardMembersInd>
      <DecisionsSubjectToApprovaInd>0</DecisionsSubjectToApprovaInd>
      <MinutesOfGoverningBodyInd>1</MinutesOfGoverningBodyInd>
      <MinutesOfCommitteesInd>1</MinutesOfCommitteesInd>
      <OfficerMailingAddressInd>0</OfficerMailingAddressInd>
      <LocalChaptersInd>0</LocalChaptersInd>
      <Form990ProvidedToGvrnBodyInd>1</Form990ProvidedToGvrnBodyInd>
      <ConflictOfInterestPolicyInd>1</ConflictOfInterestPolicyInd>
      <AnnualDisclosureCoveredPrsnInd>1</AnnualDisclosureCoveredPrsnInd>
      <RegularMonitoringEnfrcInd>1</RegularMonitoringEnfrcInd>
      <WhistleblowerPolicyInd>1</WhistleblowerPolicyInd>
      <DocumentRetentionPolicyInd>1</DocumentRetentionPolicyInd>
      <CompensationProcessCEOInd>1</CompensationProcessCEOInd>
      <CompensationProcessOtherInd>1</CompensationProcessOtherInd>
      <InvestmentInJointVentureInd>0</InvestmentInJointVentureInd>
      <StatesWhereCopyOfReturnIsFldCd>AL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AR</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CO</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>FL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>GA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>HI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>IL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>KS</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>KY</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>ME</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MD</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MN</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MO</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NV</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NH</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NJ</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NM</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NY</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OH</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OK</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OR</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>PA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>SC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>TN</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>UT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>VA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WV</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WI</StatesWhereCopyOfReturnIsFldCd>
      <UponRequestInd>X</UponRequestInd>
      <BooksInCareOfDetail>
        <BusinessName>
          <BusinessNameLine1Txt>FAISAL JAWAID</BusinessNameLine1Txt>
        </BusinessName>
        <PhoneNum>5167371555</PhoneNum>
        <USAddress>
          <AddressLine1Txt>415 CROSSWAYS PARK DRIVE SUITE D</AddressLine1Txt>
          <CityNm>WOODBURY</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>11797</ZIPCd>
        </USAddress>
      </BooksInCareOfDetail>
      <Form990PartVIISectionAGrp>
        <PersonNm>ANDREW LUSTGARTEN</PersonNm>
        <TitleTxt>CHAIRMAN</TitleTxt>
        <AverageHoursPerWeekRt>5.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JAMES DOLAN</PersonNm>
        <TitleTxt>VICE CHAIRMAN</TitleTxt>
        <AverageHoursPerWeekRt>2.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>ADAM SILVER</PersonNm>
        <TitleTxt>VICE CHAIRMAN</TitleTxt>
        <AverageHoursPerWeekRt>2.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>CHARLES F DOLAN</PersonNm>
        <TitleTxt>CHAIRMAN EMERITUS</TitleTxt>
        <AverageHoursPerWeekRt>2.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>ROBERT F VIZZA PHD</PersonNm>
        <TitleTxt>CHAIRMAN EMERITUS (END 5/9/2020)</TitleTxt>
        <AverageHoursPerWeekRt>35.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>580751</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>9086</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>WILLIAM BELL</PersonNm>
        <TitleTxt>TREASURER</TitleTxt>
        <AverageHoursPerWeekRt>2.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JOHN H COBB</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>2.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JESSICA LUSTGARTEN COURTEMANCHE</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>2.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>QUENTIN F DOLAN</PersonNm>
        <TitleTxt>TRUSTEE</TitleTxt>
        <AverageHoursPerWeekRt>2.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JENNIE FORTUNOFF</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>2.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>KEN GOODMAN MD FACR</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>2.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MARCIA LUSTGARTEN</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>2.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>SHEILA MAHONY</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>2.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>CHARLES R SCHUELER</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>2.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>WILLA SHALIT</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>2.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>LINDA TANTAWI</PersonNm>
        <TitleTxt>CHIEF EXEC OFCR (START 12/1/20)</TitleTxt>
        <AverageHoursPerWeekRt>40.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>24334</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>2726</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>KERRI KAPLAN</PersonNm>
        <TitleTxt>PRESIDENT, VP OF MAJOR GIFTS</TitleTxt>
        <AverageHoursPerWeekRt>45.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>331122</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>28378</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JOHANNA RICHMAN</PersonNm>
        <TitleTxt>CHIEF FIN OFCR (START 9/21/20)</TitleTxt>
        <AverageHoursPerWeekRt>40.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>62137</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>6605</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>CATHERINE WEBER</PersonNm>
        <TitleTxt>VP DEVELOPMENT OPERATIONS</TitleTxt>
        <AverageHoursPerWeekRt>40.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>195829</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>30404</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>STEPHANIE H ELSEA</PersonNm>
        <TitleTxt>VP MARKETING &amp; COMMUNICATIONS</TitleTxt>
        <AverageHoursPerWeekRt>40.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>187756</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>18812</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>ANDREW S RAKEMAN</PersonNm>
        <TitleTxt>VICE PRESIDENT OF RESEARCH</TitleTxt>
        <AverageHoursPerWeekRt>40.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>158491</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>32179</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JASON RICE</PersonNm>
        <TitleTxt>NATIONAL DIRECTOR OF EVENTS</TitleTxt>
        <AverageHoursPerWeekRt>40.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.00</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>139045</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>5000</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <TotalReportableCompFromOrgAmt>1679465</TotalReportableCompFromOrgAmt>
      <TotReportableCompRltdOrgAmt>0</TotReportableCompRltdOrgAmt>
      <TotalOtherCompensationAmt>133190</TotalOtherCompensationAmt>
      <IndivRcvdGreaterThan100KCnt>6</IndivRcvdGreaterThan100KCnt>
      <FormerOfcrEmployeesListedInd>0</FormerOfcrEmployeesListedInd>
      <TotalCompGreaterThan150KInd>1</TotalCompGreaterThan150KInd>
      <CompensationFromOtherSrcsInd>0</CompensationFromOtherSrcsInd>
      <ContractorCompensationGrp>
        <ContractorName>
          <BusinessName>
            <BusinessNameLine1Txt>FAIRCOM NEW YORK</BusinessNameLine1Txt>
          </BusinessName>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>12 WEST 27TH STREET 13TH FL SUITE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10001</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>MARKETING</ServicesDesc>
        <CompensationAmt>620963</CompensationAmt>
      </ContractorCompensationGrp>
      <CntrctRcvdGreaterThan100KCnt>1</CntrctRcvdGreaterThan100KCnt>
      <FundraisingAmt>3378483</FundraisingAmt>
      <AllOtherContributionsAmt>12283125</AllOtherContributionsAmt>
      <NoncashContributionsAmt>142960</NoncashContributionsAmt>
      <TotalContributionsAmt>15661608</TotalContributionsAmt>
      <InvestmentIncomeGrp>
        <TotalRevenueColumnAmt>1890317</TotalRevenueColumnAmt>
        <ExclusionAmt>1890317</ExclusionAmt>
      </InvestmentIncomeGrp>
      <RoyaltiesRevenueGrp>
        <TotalRevenueColumnAmt>1361709</TotalRevenueColumnAmt>
        <ExclusionAmt>1361709</ExclusionAmt>
      </RoyaltiesRevenueGrp>
      <GrossAmountSalesAssetsGrp>
        <SecuritiesAmt>76978283</SecuritiesAmt>
      </GrossAmountSalesAssetsGrp>
      <LessCostOthBasisSalesExpnssGrp>
        <SecuritiesAmt>71224359</SecuritiesAmt>
      </LessCostOthBasisSalesExpnssGrp>
      <GainOrLossGrp>
        <SecuritiesAmt>5753924</SecuritiesAmt>
      </GainOrLossGrp>
      <NetGainOrLossInvestmentsGrp>
        <TotalRevenueColumnAmt>5753924</TotalRevenueColumnAmt>
        <ExclusionAmt>5753924</ExclusionAmt>
      </NetGainOrLossInvestmentsGrp>
      <FundraisingGrossIncomeAmt>8150</FundraisingGrossIncomeAmt>
      <ContriRptFundraisingEventAmt>3378483</ContriRptFundraisingEventAmt>
      <FundraisingDirectExpensesAmt>207875</FundraisingDirectExpensesAmt>
      <NetIncmFromFundraisingEvtGrp>
        <TotalRevenueColumnAmt>-199725</TotalRevenueColumnAmt>
        <ExclusionAmt>-199725</ExclusionAmt>
      </NetIncmFromFundraisingEvtGrp>
      <TotalRevenueGrp>
        <TotalRevenueColumnAmt>24467833</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>8806225</ExclusionAmt>
      </TotalRevenueGrp>
      <GrantsToDomesticOrgsGrp>
        <TotalAmt>15342948</TotalAmt>
        <ProgramServicesAmt>15342948</ProgramServicesAmt>
      </GrantsToDomesticOrgsGrp>
      <ForeignGrantsGrp>
        <TotalAmt>399952</TotalAmt>
        <ProgramServicesAmt>399952</ProgramServicesAmt>
      </ForeignGrantsGrp>
      <CompCurrentOfcrDirectorsGrp>
        <TotalAmt>989673</TotalAmt>
        <ProgramServicesAmt>326592</ProgramServicesAmt>
        <ManagementAndGeneralAmt>257315</ManagementAndGeneralAmt>
        <FundraisingAmt>405766</FundraisingAmt>
      </CompCurrentOfcrDirectorsGrp>
      <OtherSalariesAndWagesGrp>
        <TotalAmt>1609792</TotalAmt>
        <ProgramServicesAmt>531231</ProgramServicesAmt>
        <ManagementAndGeneralAmt>418546</ManagementAndGeneralAmt>
        <FundraisingAmt>660015</FundraisingAmt>
      </OtherSalariesAndWagesGrp>
      <PensionPlanContributionsGrp>
        <TotalAmt>50661</TotalAmt>
        <ProgramServicesAmt>16718</ProgramServicesAmt>
        <ManagementAndGeneralAmt>13172</ManagementAndGeneralAmt>
        <FundraisingAmt>20771</FundraisingAmt>
      </PensionPlanContributionsGrp>
      <OtherEmployeeBenefitsGrp>
        <TotalAmt>261482</TotalAmt>
        <ProgramServicesAmt>86290</ProgramServicesAmt>
        <ManagementAndGeneralAmt>67984</ManagementAndGeneralAmt>
        <FundraisingAmt>107208</FundraisingAmt>
      </OtherEmployeeBenefitsGrp>
      <PayrollTaxesGrp>
        <TotalAmt>118577</TotalAmt>
        <ProgramServicesAmt>39130</ProgramServicesAmt>
        <ManagementAndGeneralAmt>30830</ManagementAndGeneralAmt>
        <FundraisingAmt>48617</FundraisingAmt>
      </PayrollTaxesGrp>
      <FeesForServicesProfFundraising>
        <TotalAmt>697612</TotalAmt>
        <FundraisingAmt>697612</FundraisingAmt>
      </FeesForServicesProfFundraising>
      <FeesForSrvcInvstMgmntFeesGrp>
        <TotalAmt>286230</TotalAmt>
        <ManagementAndGeneralAmt>286230</ManagementAndGeneralAmt>
      </FeesForSrvcInvstMgmntFeesGrp>
      <FeesForServicesOtherGrp>
        <TotalAmt>549510</TotalAmt>
        <ProgramServicesAmt>263555</ProgramServicesAmt>
        <ManagementAndGeneralAmt>285955</ManagementAndGeneralAmt>
      </FeesForServicesOtherGrp>
      <AdvertisingGrp>
        <TotalAmt>205648</TotalAmt>
        <ProgramServicesAmt>205648</ProgramServicesAmt>
      </AdvertisingGrp>
      <OfficeExpensesGrp>
        <TotalAmt>417071</TotalAmt>
        <ProgramServicesAmt>146756</ProgramServicesAmt>
        <ManagementAndGeneralAmt>107855</ManagementAndGeneralAmt>
        <FundraisingAmt>162460</FundraisingAmt>
      </OfficeExpensesGrp>
      <InformationTechnologyGrp>
        <TotalAmt>150385</TotalAmt>
        <ProgramServicesAmt>110283</ProgramServicesAmt>
        <ManagementAndGeneralAmt>40102</ManagementAndGeneralAmt>
      </InformationTechnologyGrp>
      <OccupancyGrp>
        <TotalAmt>236153</TotalAmt>
        <ProgramServicesAmt>106267</ProgramServicesAmt>
        <ManagementAndGeneralAmt>35425</ManagementAndGeneralAmt>
        <FundraisingAmt>94461</FundraisingAmt>
      </OccupancyGrp>
      <ConferencesMeetingsGrp>
        <TotalAmt>33489</TotalAmt>
        <FundraisingAmt>33489</FundraisingAmt>
      </ConferencesMeetingsGrp>
      <DepreciationDepletionGrp>
        <TotalAmt>84883</TotalAmt>
        <ProgramServicesAmt>37348</ProgramServicesAmt>
        <ManagementAndGeneralAmt>13582</ManagementAndGeneralAmt>
        <FundraisingAmt>33953</FundraisingAmt>
      </DepreciationDepletionGrp>
      <InsuranceGrp>
        <TotalAmt>40307</TotalAmt>
        <ProgramServicesAmt>17956</ProgramServicesAmt>
        <ManagementAndGeneralAmt>6391</ManagementAndGeneralAmt>
        <FundraisingAmt>15960</FundraisingAmt>
      </InsuranceGrp>
      <OtherExpensesGrp>
        <Desc>BANK AND CREDIT CARD FE</Desc>
        <TotalAmt>150711</TotalAmt>
        <ManagementAndGeneralAmt>10808</ManagementAndGeneralAmt>
        <FundraisingAmt>139903</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>RESEARCH SUPPORT</Desc>
        <TotalAmt>82687</TotalAmt>
        <ProgramServicesAmt>82687</ProgramServicesAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>OTHER</Desc>
        <TotalAmt>18258</TotalAmt>
        <ProgramServicesAmt>8033</ProgramServicesAmt>
        <ManagementAndGeneralAmt>2923</ManagementAndGeneralAmt>
        <FundraisingAmt>7302</FundraisingAmt>
      </OtherExpensesGrp>
      <TotalFunctionalExpensesGrp>
        <TotalAmt>21726029</TotalAmt>
        <ProgramServicesAmt>17721394</ProgramServicesAmt>
        <ManagementAndGeneralAmt>1577118</ManagementAndGeneralAmt>
        <FundraisingAmt>2427517</FundraisingAmt>
      </TotalFunctionalExpensesGrp>
      <CashNonInterestBearingGrp>
        <BOYAmt>1910337</BOYAmt>
        <EOYAmt>4253446</EOYAmt>
      </CashNonInterestBearingGrp>
      <PledgesAndGrantsReceivableGrp>
        <BOYAmt>318852</BOYAmt>
        <EOYAmt>515050</EOYAmt>
      </PledgesAndGrantsReceivableGrp>
      <AccountsReceivableGrp>
        <EOYAmt>1508338</EOYAmt>
      </AccountsReceivableGrp>
      <PrepaidExpensesDefrdChargesGrp>
        <BOYAmt>174487</BOYAmt>
        <EOYAmt>190633</EOYAmt>
      </PrepaidExpensesDefrdChargesGrp>
      <LandBldgEquipCostOrOtherBssAmt>237050</LandBldgEquipCostOrOtherBssAmt>
      <LandBldgEquipAccumDeprecAmt>105420</LandBldgEquipAccumDeprecAmt>
      <LandBldgEquipBasisNetGrp>
        <BOYAmt>165524</BOYAmt>
        <EOYAmt>131630</EOYAmt>
      </LandBldgEquipBasisNetGrp>
      <InvestmentsPubTradedSecGrp>
        <BOYAmt>87982180</BOYAmt>
        <EOYAmt>89962535</EOYAmt>
      </InvestmentsPubTradedSecGrp>
      <TotalAssetsGrp>
        <BOYAmt>90551380</BOYAmt>
        <EOYAmt>96561632</EOYAmt>
      </TotalAssetsGrp>
      <AccountsPayableAccrExpnssGrp>
        <BOYAmt>478590</BOYAmt>
        <EOYAmt>533611</EOYAmt>
      </AccountsPayableAccrExpnssGrp>
      <GrantsPayableGrp>
        <BOYAmt>8774834</BOYAmt>
        <EOYAmt>2997905</EOYAmt>
      </GrantsPayableGrp>
      <DeferredRevenueGrp>
        <BOYAmt>480772</BOYAmt>
      </DeferredRevenueGrp>
      <OtherLiabilitiesGrp>
        <BOYAmt>76877</BOYAmt>
        <EOYAmt>82959</EOYAmt>
      </OtherLiabilitiesGrp>
      <TotalLiabilitiesGrp>
        <BOYAmt>9811073</BOYAmt>
        <EOYAmt>3614475</EOYAmt>
      </TotalLiabilitiesGrp>
      <OrganizationFollowsFASB117Ind>X</OrganizationFollowsFASB117Ind>
      <NoDonorRestrictionNetAssetsGrp>
        <BOYAmt>80376307</BOYAmt>
        <EOYAmt>92560157</EOYAmt>
      </NoDonorRestrictionNetAssetsGrp>
      <DonorRestrictionNetAssetsGrp>
        <BOYAmt>364000</BOYAmt>
        <EOYAmt>387000</EOYAmt>
      </DonorRestrictionNetAssetsGrp>
      <TotalNetAssetsFundBalanceGrp>
        <BOYAmt>80740307</BOYAmt>
        <EOYAmt>92947157</EOYAmt>
      </TotalNetAssetsFundBalanceGrp>
      <TotLiabNetAssetsFundBalanceGrp>
        <BOYAmt>90551380</BOYAmt>
        <EOYAmt>96561632</EOYAmt>
      </TotLiabNetAssetsFundBalanceGrp>
      <ReconcilationRevenueExpnssAmt>2741804</ReconcilationRevenueExpnssAmt>
      <NetUnrlzdGainsLossesInvstAmt>9465046</NetUnrlzdGainsLossesInvstAmt>
      <OtherChangesInNetAssetsAmt>0</OtherChangesInNetAssetsAmt>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AccountantCompileOrReviewInd>0</AccountantCompileOrReviewInd>
      <FSAuditedInd>1</FSAuditedInd>
      <FSAuditedBasisGrp>
        <SeparateBasisFinclStmtInd>X</SeparateBasisFinclStmtInd>
      </FSAuditedBasisGrp>
      <AuditCommitteeInd>1</AuditCommitteeInd>
      <FederalGrantAuditRequiredInd>0</FederalGrantAuditRequiredInd>
    </IRS990>
    <IRS990ScheduleA documentId="RetDoc1039100001">
      <PublicOrganization170Ind>X</PublicOrganization170Ind>
      <GiftsGrantsContriRcvd170Grp>
        <CurrentTaxYearMinus4YearsAmt>43176330</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>12048978</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>15969356</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>13046433</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>15661608</CurrentTaxYearAmt>
        <TotalAmt>99902705</TotalAmt>
      </GiftsGrantsContriRcvd170Grp>
      <TotalCalendarYear170Grp>
        <CurrentTaxYearMinus4YearsAmt>43176330</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>12048978</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>15969356</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>13046433</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>15661608</CurrentTaxYearAmt>
        <TotalAmt>99902705</TotalAmt>
      </TotalCalendarYear170Grp>
      <SubstantialContributorsTotAmt>38962370</SubstantialContributorsTotAmt>
      <PublicSupportTotal170Amt>60940335</PublicSupportTotal170Amt>
      <GrossInvestmentIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>1377642</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>515595</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>1755392</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>2417283</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>3252026</CurrentTaxYearAmt>
        <TotalAmt>9317938</TotalAmt>
      </GrossInvestmentIncome170Grp>
      <OtherIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>349626</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>99169</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>371093</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>219523</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>8150</CurrentTaxYearAmt>
        <TotalAmt>1047561</TotalAmt>
      </OtherIncome170Grp>
      <TotalSupportAmt>110268204</TotalSupportAmt>
      <PublicSupportCY170Pct>0.55270</PublicSupportCY170Pct>
      <PublicSupportPY170Pct>0.52850</PublicSupportPY170Pct>
      <ThirtyThrPctSuprtTestsCY170Ind>X</ThirtyThrPctSuprtTestsCY170Ind>
      <Form990ScheduleAPartVIGrp>
        <FormAndLineReferenceDesc>SCHEDULE A, PART II</FormAndLineReferenceDesc>
        <ExplanationTxt>THE FOUNDATION CHANGED ITS FISCAL YEAR END DATE TO JUNE 30TH IN 2018, RESULTING IN A SHORT PERIOD TAX YEAR OF SIX MONTHS FROM JANUARY 1 - JUNE 30, 2018. AS A RESULT, AMOUNTS REPORTED IN COLUMN (B) REFLECT AMOUNTS FOR THE SHORT PERIOD JANUARY 1, 2018 - JUNE 30, 2018. COLUMN (A) REFLECTS AMOUNTS REPORTED FOR CALENDAR YEAR 2017. AMOUNTS ON LINE 10 REPRESENT GROSS INCOME FROM FUNDRAISING EVENTS.</ExplanationTxt>
      </Form990ScheduleAPartVIGrp>
    </IRS990ScheduleA>
    <IRS990ScheduleB documentId="RetDoc1234500001">
      <ContributorInformationGrp>
        <ContributorNum>RESTRICTED</ContributorNum>
        <ContributorBusinessName>
          <BusinessNameLine1>RESTRICTED</BusinessNameLine1>
        </ContributorBusinessName>
        <ContributorUSAddress>
          <AddressLine1>RESTRICTED</AddressLine1>
          <AddressLine2>RESTRICTED</AddressLine2>
          <City>RESTRICTED</City>
          <State>RESTRICTED</State>
          <ZIPCode>RESTRICTED</ZIPCode>
        </ContributorUSAddress>
        <TotalContributionsAmt>RESTRICTED</TotalContributionsAmt>
      </ContributorInformationGrp>
    </IRS990ScheduleB>
    <IRS990ScheduleD documentId="RetDoc1040000001">
      <LeaseholdImprovementsGrp>
        <OtherCostOrOtherBasisAmt>5865</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>3603</DepreciationAmt>
        <BookValueAmt>2262</BookValueAmt>
      </LeaseholdImprovementsGrp>
      <EquipmentGrp>
        <OtherCostOrOtherBasisAmt>18631</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>6175</DepreciationAmt>
        <BookValueAmt>12456</BookValueAmt>
      </EquipmentGrp>
      <OtherLandBuildingsGrp>
        <OtherCostOrOtherBasisAmt>212554</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>95642</DepreciationAmt>
        <BookValueAmt>116912</BookValueAmt>
      </OtherLandBuildingsGrp>
      <TotalBookValueLandBuildingsAmt>131630</TotalBookValueLandBuildingsAmt>
      <OtherLiabilitiesOrgGrp>
        <Desc>DEFERRED RENT OBLIGATION</Desc>
        <Amt>82959</Amt>
      </OtherLiabilitiesOrgGrp>
      <TotalLiabilityAmt>82959</TotalLiabilityAmt>
      <FootnoteTextInd>X</FootnoteTextInd>
      <TotalRevEtcAuditedFinclStmtAmt>38277396</TotalRevEtcAuditedFinclStmtAmt>
      <NetUnrealizedGainsInvstAmt>9465046</NetUnrealizedGainsInvstAmt>
      <DonatedServicesAndUseFcltsAmt>4630747</DonatedServicesAndUseFcltsAmt>
      <RevenueNotReportedAmt>14095793</RevenueNotReportedAmt>
      <RevenueSubtotalAmt>24181603</RevenueSubtotalAmt>
      <InvestmentExpensesNotIncldAmt>286230</InvestmentExpensesNotIncldAmt>
      <RevenueNotReportedFinclStmtAmt>286230</RevenueNotReportedFinclStmtAmt>
      <TotalRevenuePerForm990Amt>24467833</TotalRevenuePerForm990Amt>
      <TotExpnsEtcAuditedFinclStmtAmt>26070546</TotExpnsEtcAuditedFinclStmtAmt>
      <DonatedServicesUseFcltsAmt>4630747</DonatedServicesUseFcltsAmt>
      <ExpensesNotReportedAmt>4630747</ExpensesNotReportedAmt>
      <ExpensesSubtotalAmt>21439799</ExpensesSubtotalAmt>
      <InvestmentExpensesNotIncld2Amt>286230</InvestmentExpensesNotIncld2Amt>
      <ExpensesNotRptFinclStmtAmt>286230</ExpensesNotRptFinclStmtAmt>
      <TotalExpensesPerForm990Amt>21726029</TotalExpensesPerForm990Amt>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART X, LINE 2:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE FOUNDATION HAS RECEIVED A FINAL DETERMINATION LETTER FROM THE INTERNAL REVENUE SERVICE STATING THAT THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAX UNDER SECTION 501(C)(3). THE FOUNDATION IS TREATED AS A PUBLIC CHARITY AS DEFINED IN SECTIONS 509(A)(1) AND 170(B)(1)(A)(VI). THE FOUNDATION FOLLOWS THE PROVISIONS OF ACCOUNTING STANDARDS CODIFICATION (ASC) SUBTOPIC 740-10, INCOME TAXES - OVERALL (ASC 740-10), RELATING TO UNCERTAINTY IN INCOME TAXES. FOR THE FOUNDATION, ASC 740-10 IS PRIMARILY APPLICABLE TO THE INCURRENCE OF UNRELATED BUSINESS INCOME TAX ATTRIBUTABLE TO CERTAIN OF ITS INVESTMENTS. ASC 740-10 ESTABLISHES A MINIMUM THRESHOLD FOR FINANCIAL STATEMENT RECOGNITION OF THE BENEFITS OF POSITIONS TAKEN, OR EXPECTED TO BE TAKEN, IN FILING TAX RETURNS. IT REQUIRES THE EVALUATION OF TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN, IN THE COURSE OF PREPARING THE FOUNDATION'S INCOME TAX RETURNS TO DETERMINE WHETHER THE TAX POSITIONS ARE "MORE LIKELY THAN NOT" OF BEING SUSTAINED BY THE APPLICABLE TAX AUTHORITY. TAX POSITIONS NOT DEEMED TO MEET THE MORE-LIKELY THAN-NOT THRESHOLD ARE RECORDED AS TAX EXPENSE. FOR THE YEARS ENDED JUNE 30, 2021 AND 2020, THE FOUNDATION HAS NOT IDENTIFIED OR PROVIDED FOR ANY SUCH POSITIONS.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleD>
    <IRS990ScheduleF documentId="RetDoc1040500001">
      <GrantRecordsMaintainedInd>1</GrantRecordsMaintainedInd>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>EUROPE (INCLUDING ICELAND &amp; GREENLAND)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>GRANTMAKING</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>PANCREATIC CANCER RESEARCH</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>200000</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>NORTH AMERICA</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>GRANTMAKING</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>PANCREATIC CANCER RESEARCH</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>199952</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <SubtotalOfficesCnt>0</SubtotalOfficesCnt>
      <SubtotalEmployeesCnt>0</SubtotalEmployeesCnt>
      <ContinuationTotalOfficeCnt>0</ContinuationTotalOfficeCnt>
      <ContinuationTotalEmployeeCnt>0</ContinuationTotalEmployeeCnt>
      <TotalOfficeCnt>0</TotalOfficeCnt>
      <TotalEmployeeCnt>0</TotalEmployeeCnt>
      <SubtotalSpentAmt>399952</SubtotalSpentAmt>
      <ContinuationSpentAmt>0</ContinuationSpentAmt>
      <TotalSpentAmt>399952</TotalSpentAmt>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>EUROPE (INCLUDING ICELAND &amp; GREENLAND)</RegionTxt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
        <CashGrantAmt>200000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>WIRE/EFT</MannerOfCashDisbursementTxt>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>NORTH AMERICA</RegionTxt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
        <CashGrantAmt>199952</CashGrantAmt>
        <MannerOfCashDisbursementTxt>WIRE/EFT</MannerOfCashDisbursementTxt>
      </GrantsToOrgOutsideUSGrp>
      <Total501c3OrgCnt>2</Total501c3OrgCnt>
      <TotalOtherOrgCnt>0</TotalOtherOrgCnt>
      <TransferToForeignCorpInd>0</TransferToForeignCorpInd>
      <InterestInForeignTrustInd>0</InterestInForeignTrustInd>
      <ForeignCorpOwnershipInd>0</ForeignCorpOwnershipInd>
      <PassiveForeignInvestmestCoInd>0</PassiveForeignInvestmestCoInd>
      <ForeignPartnershipInd>0</ForeignPartnershipInd>
      <BoycottCountriesInd>0</BoycottCountriesInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART III ACCOUNTING METHOD:</FormAndLineReferenceDesc>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SCHEDULE F, PART I, LINE 2</FormAndLineReferenceDesc>
        <ExplanationTxt>GRANT MONITORING PROCESS THE ORGANIZATION REQUIRES ALL GRANTEES TO PROVIDE DETAILED REPORTING ON THEIR RESEARCH. THAT REPORTING INCLUDES ACCOUNTING FOR ALL FUNDS AND SHALL BE ACCOMPANIED BY ELECTRONIC COPIES OF ALL ARTICLES, IRRESPECTIVE OF WHETHER THEY WERE PUBLISHED, PRESENTED OR OTHERWISE DISCLOSED, CONCERNING GRANT RESEARCH WRITTEN BY THE PRINCIPAL INVESTIGATOR. FINAL GRANT ACCOUNTING IS DUE FROM THE SPONSORING INSTITUTION AND THE INSTITUTIONS AGREE TO REFUND ANY PORTION OF THE GRANT FUNDS TO THE FOUNDATION THAT WAS NOT USED FOR THE SPECIFIED PURPOSES DESCRIBED HEREIN AND RETURN TO THE FOUNDATION ANY UNEXPENDED FUNDS WITHIN THIRTY (30) DAYS AFTER THE EXPIRATION OR TERMINATION OF THE GRANT TERM, OR, AT THE FOUNDATION'S OPTION, THE FOUNDATION MAY, BY WRITTEN NOTICE, ALLOW THE SPONSORING INSTITUTION TO USE ANY REMAINING GRANT FUNDS IN FURTHERANCE OF GRANT RESEARCH IN PROGRESS AT THE TIME OF SUCH EXPIRATION. THE FOUNDATION SHALL HAVE THE RIGHT TO AUDIT THE USE OF GRANT FUNDS.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleF>
    <IRS990ScheduleG documentId="RetDoc1041200001">
      <MailSolicitationsInd>X</MailSolicitationsInd>
      <EmailSolicitationsInd>X</EmailSolicitationsInd>
      <InPersonSolicitationsInd>X</InPersonSolicitationsInd>
      <SolicitationOfNonGovtGrantsInd>X</SolicitationOfNonGovtGrantsInd>
      <SpecialFundraisingEventsInd>X</SpecialFundraisingEventsInd>
      <AgrmtProfFundraisingActyInd>1</AgrmtProfFundraisingActyInd>
      <FundraiserActivityInfoGrp>
        <OrganizationBusinessName>
          <BusinessNameLine1Txt>FAIRCOM NEW YORK</BusinessNameLine1Txt>
        </OrganizationBusinessName>
        <USAddress>
          <AddressLine1Txt>12 WEST 27TH ST</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10001</ZIPCd>
        </USAddress>
        <ActivityTxt>DIRECT MAIL &amp; MARKETING</ActivityTxt>
        <FundraiserControlOfFundsInd>0</FundraiserControlOfFundsInd>
        <GrossReceiptsAmt>1029210</GrossReceiptsAmt>
        <RetainedByContractorAmt>620963</RetainedByContractorAmt>
        <NetToOrganizationAmt>408247</NetToOrganizationAmt>
      </FundraiserActivityInfoGrp>
      <FundraiserActivityInfoGrp>
        <OrganizationBusinessName>
          <BusinessNameLine1Txt>BUCKLEY EVENTS</BusinessNameLine1Txt>
        </OrganizationBusinessName>
        <USAddress>
          <AddressLine1Txt>17 MARBLE AVE 19</AddressLine1Txt>
          <CityNm>PLEASANTVILLE</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10570</ZIPCd>
        </USAddress>
        <ActivityTxt>EVENT CONSULTING</ActivityTxt>
        <FundraiserControlOfFundsInd>0</FundraiserControlOfFundsInd>
        <GrossReceiptsAmt>532800</GrossReceiptsAmt>
        <RetainedByContractorAmt>4557</RetainedByContractorAmt>
        <NetToOrganizationAmt>528243</NetToOrganizationAmt>
      </FundraiserActivityInfoGrp>
      <FundraiserActivityInfoGrp>
        <OrganizationBusinessName>
          <BusinessNameLine1Txt>JC GREEVER INC</BusinessNameLine1Txt>
        </OrganizationBusinessName>
        <USAddress>
          <AddressLine1Txt>11 RIVERSIDE DR 2 EW</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10023</ZIPCd>
        </USAddress>
        <ActivityTxt>DONOR MANAGEMENT</ActivityTxt>
        <FundraiserControlOfFundsInd>0</FundraiserControlOfFundsInd>
        <GrossReceiptsAmt>85000</GrossReceiptsAmt>
        <RetainedByContractorAmt>72092</RetainedByContractorAmt>
        <NetToOrganizationAmt>12908</NetToOrganizationAmt>
      </FundraiserActivityInfoGrp>
      <TotalGrossReceiptsAmt>1647010</TotalGrossReceiptsAmt>
      <TotalRetainedByContractorsAmt>697612</TotalRetainedByContractorsAmt>
      <TotalNetToOrganizationAmt>949398</TotalNetToOrganizationAmt>
      <LicensedStatesCd>AL</LicensedStatesCd>
      <LicensedStatesCd>AR</LicensedStatesCd>
      <LicensedStatesCd>CA</LicensedStatesCd>
      <LicensedStatesCd>CO</LicensedStatesCd>
      <LicensedStatesCd>CT</LicensedStatesCd>
      <LicensedStatesCd>FL</LicensedStatesCd>
      <LicensedStatesCd>GA</LicensedStatesCd>
      <LicensedStatesCd>HI</LicensedStatesCd>
      <LicensedStatesCd>IL</LicensedStatesCd>
      <LicensedStatesCd>KS</LicensedStatesCd>
      <LicensedStatesCd>KY</LicensedStatesCd>
      <LicensedStatesCd>ME</LicensedStatesCd>
      <LicensedStatesCd>MD</LicensedStatesCd>
      <LicensedStatesCd>MA</LicensedStatesCd>
      <LicensedStatesCd>MI</LicensedStatesCd>
      <LicensedStatesCd>MN</LicensedStatesCd>
      <LicensedStatesCd>MO</LicensedStatesCd>
      <LicensedStatesCd>NV</LicensedStatesCd>
      <LicensedStatesCd>NH</LicensedStatesCd>
      <LicensedStatesCd>NJ</LicensedStatesCd>
      <LicensedStatesCd>NM</LicensedStatesCd>
      <LicensedStatesCd>NY</LicensedStatesCd>
      <LicensedStatesCd>NC</LicensedStatesCd>
      <LicensedStatesCd>OH</LicensedStatesCd>
      <LicensedStatesCd>OK</LicensedStatesCd>
      <LicensedStatesCd>OR</LicensedStatesCd>
      <LicensedStatesCd>PA</LicensedStatesCd>
      <LicensedStatesCd>SC</LicensedStatesCd>
      <LicensedStatesCd>TN</LicensedStatesCd>
      <LicensedStatesCd>UT</LicensedStatesCd>
      <LicensedStatesCd>VA</LicensedStatesCd>
      <LicensedStatesCd>WA</LicensedStatesCd>
      <LicensedStatesCd>WV</LicensedStatesCd>
      <LicensedStatesCd>WI</LicensedStatesCd>
      <FundraisingEventInformationGrp>
        <Event1Nm>SPRING GALA</Event1Nm>
        <GrossReceiptsEvent1Amt>532800</GrossReceiptsEvent1Amt>
        <CharitableContriEvent1Amt>532800</CharitableContriEvent1Amt>
        <FoodAndBeverageEvent1Amt>309</FoodAndBeverageEvent1Amt>
        <OtherDirectExpensesEvent1Amt>5715</OtherDirectExpensesEvent1Amt>
        <Event2Nm>HOLIDAY BASH</Event2Nm>
        <GrossReceiptsEvent2Amt>172606</GrossReceiptsEvent2Amt>
        <CharitableContriEvent2Amt>167606</CharitableContriEvent2Amt>
        <GrossRevenueEvent2Amt>5000</GrossRevenueEvent2Amt>
        <FoodAndBeverageEvent2Amt>47</FoodAndBeverageEvent2Amt>
        <EntertainmentEvent2Amt>700</EntertainmentEvent2Amt>
        <OtherDirectExpensesEvent2Amt>9840</OtherDirectExpensesEvent2Amt>
        <OtherEventsTotalCnt>57</OtherEventsTotalCnt>
        <GrossReceiptsOtherEventsAmt>2681227</GrossReceiptsOtherEventsAmt>
        <CharitableContriOtherEventsAmt>2678077</CharitableContriOtherEventsAmt>
        <GrossRevenueOtherEventsAmt>3150</GrossRevenueOtherEventsAmt>
        <EntertainmentOtherEventsAmt>111</EntertainmentOtherEventsAmt>
        <OthDirectExpnssOtherEventsAmt>191153</OthDirectExpnssOtherEventsAmt>
        <GrossReceiptsTotalAmt>3386633</GrossReceiptsTotalAmt>
        <CharitableContributionsTotAmt>3378483</CharitableContributionsTotAmt>
        <GrossRevenueTotalEventsAmt>8150</GrossRevenueTotalEventsAmt>
        <FoodAndBeverageTotalEventsAmt>356</FoodAndBeverageTotalEventsAmt>
        <EntertainmentTotalEventsAmt>811</EntertainmentTotalEventsAmt>
        <OthDirectExpnssTotalEventsAmt>206708</OthDirectExpnssTotalEventsAmt>
        <DirectExpenseSummaryEventsAmt>207875</DirectExpenseSummaryEventsAmt>
        <NetIncomeSummaryAmt>-199725</NetIncomeSummaryAmt>
      </FundraisingEventInformationGrp>
    </IRS990ScheduleG>
    <IRS990ScheduleI documentId="RetDoc1041900001">
      <GrantRecordsMaintainedInd>1</GrantRecordsMaintainedInd>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>AMERICAN ASSOCIATION FOR CANCER RESEARCH</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>615 CHESTNUT ST</AddressLine1Txt>
          <CityNm>PHILADELPHIA</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>191064404</ZIPCd>
        </USAddress>
        <RecipientEIN>236251648</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>220000</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>300 LONGWOOD AVENUE</AddressLine1Txt>
          <CityNm>BOSTON</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02115</ZIPCd>
        </USAddress>
        <RecipientEIN>431987409</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>30000</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>COLD SPRING HARBOR LABORATORY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>ONE BUNGTOWN RD</AddressLine1Txt>
          <CityNm>COLD SPRING HBR</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>11724</ZIPCd>
        </USAddress>
        <RecipientEIN>112013303</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>1032223</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>THE TRUSTEES OF COLUMBIA UNIV IN THE CITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>615 W 13TH ST MC 8741</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10027</ZIPCd>
        </USAddress>
        <RecipientEIN>135598093</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>421735</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>DANA FARBER CANCER INSTITUTE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>450 BROOKLINE AVENUE</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>02215</ZIPCd>
        </USAddress>
        <RecipientEIN>042263040</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>1491911</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>HENRY FORD HEALTH SYSTEM</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1 FORD PLACE RESEARCH ADMINISTRATIO</AddressLine1Txt>
          <AddressLine2Txt>2F</AddressLine2Txt>
          <CityNm>DETRIOT</CityNm>
          <StateAbbreviationCd>MI</StateAbbreviationCd>
          <ZIPCd>48202</ZIPCd>
        </USAddress>
        <RecipientEIN>381357020</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>75000</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>JOHNS HOPKINS UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1650 ORLEANS STREET</AddressLine1Txt>
          <CityNm>BALTIMORE</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>21287</ZIPCd>
        </USAddress>
        <RecipientEIN>520595110</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>2222732</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>MASSACHUSETTS INSTITUTE OF TECHNOLOGY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>77 MASSACHUSETTS AVENUE</AddressLine1Txt>
          <CityNm>CAMBRIDGE</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02139</ZIPCd>
        </USAddress>
        <RecipientEIN>042103594</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>656821</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>NEW YORK UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>ONE PARK AVE 6TH FL</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10016</ZIPCd>
        </USAddress>
        <RecipientEIN>135562308</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>200000</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>OREGON HEALTH &amp; SCIENCE UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3181 SW SAM JACKSON PARK RD MAIL</AddressLine1Txt>
          <AddressLine2Txt>CODEL106</AddressLine2Txt>
          <CityNm>PORTLAND</CityNm>
          <StateAbbreviationCd>OR</StateAbbreviationCd>
          <ZIPCd>97239</ZIPCd>
        </USAddress>
        <RecipientEIN>931176109</RecipientEIN>
        <IRCSectionDesc>GOV'T</IRCSectionDesc>
        <CashGrantAmt>99154</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>THE SALK INSTITUTE FOR BIOLOGICAL STUDIES</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>10010 N TORREY PINES RD</AddressLine1Txt>
          <CityNm>LA JOLLA</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92037</ZIPCd>
        </USAddress>
        <RecipientEIN>952160097</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>500000</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>STAND UP TO CANCER - ENTERTAINMENT IND FDN</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>10880 WILSHIRE BLVD STE 1400</AddressLine1Txt>
          <CityNm>LOS ANGELES</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>90024</ZIPCd>
        </USAddress>
        <RecipientEIN>951644609</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>7563373</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>9500 GILAN DRIVE DEPT 0924</AddressLine1Txt>
          <CityNm>LA JOLLA</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92093</ZIPCd>
        </USAddress>
        <RecipientEIN>956006144</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>200000</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3451 WALNUT STREET ROOM P221</AddressLine1Txt>
          <AddressLine2Txt>FRANKLIN BUILDING</AddressLine2Txt>
          <CityNm>PHILADELPHIA</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>19104</ZIPCd>
        </USAddress>
        <RecipientEIN>231352685</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>200000</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>WHITEHEAD INST FOR BIOMEDICAL RESEARCH</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>9 CAMBRIDGE CENTER</AddressLine1Txt>
          <CityNm>CAMBRIDGE</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02142</ZIPCd>
        </USAddress>
        <RecipientEIN>061043412</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>230000</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>25 SCIENCE PARK 3RD FL</AddressLine1Txt>
          <CityNm>NEW HAVEN</CityNm>
          <StateAbbreviationCd>CT</StateAbbreviationCd>
          <ZIPCd>06520</ZIPCd>
        </USAddress>
        <RecipientEIN>060646973</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>200000</CashGrantAmt>
        <PurposeOfGrantTxt>PANCREATIC CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <Total501c3OrgCnt>16</Total501c3OrgCnt>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART I, LINE 2:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE FOUNDATION MAKES GRANTS TO 501(C)(3) PUBLIC CHARITIES CONDUCTING PANCREATIC CANCER RESEARCH. AS PART OF THE REQUIREMENT FOR RECEIVING SUCH GRANTS, THE FOUNDATION REQUIRES PERIODIC UPDATES AND REPORTING ON SCIENTIFIC PROGRESS AND FINANCIAL EXPENDITURES.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleI>
    <IRS990ScheduleJ documentId="RetDoc1042400001">
      <Form990OfOtherOrganizationsInd>X</Form990OfOtherOrganizationsInd>
      <CompensationSurveyInd>X</CompensationSurveyInd>
      <BoardOrCommitteeApprovalInd>X</BoardOrCommitteeApprovalInd>
      <SeverancePaymentInd>1</SeverancePaymentInd>
      <SupplementalNonqualRtrPlanInd>0</SupplementalNonqualRtrPlanInd>
      <EquityBasedCompArrngmInd>0</EquityBasedCompArrngmInd>
      <CompBasedOnRevenueOfFlngOrgInd>0</CompBasedOnRevenueOfFlngOrgInd>
      <CompBsdOnRevRelatedOrgsInd>0</CompBsdOnRevRelatedOrgsInd>
      <CompBsdNetEarnsFlngOrgInd>0</CompBsdNetEarnsFlngOrgInd>
      <CompBsdNetEarnsRltdOrgsInd>0</CompBsdNetEarnsRltdOrgsInd>
      <AnyNonFixedPaymentsInd>1</AnyNonFixedPaymentsInd>
      <InitialContractExceptionInd>0</InitialContractExceptionInd>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>ROBERT F VIZZA PHD</PersonNm>
        <TitleTxt>CHAIRMAN EMERITUS (END 5/9/2020)</TitleTxt>
        <BaseCompensationFilingOrgAmt>136313</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>70296</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>374142</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>9086</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>589837</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>KERRI KAPLAN</PersonNm>
        <TitleTxt>PRESIDENT, VP OF MAJOR GIFTS</TitleTxt>
        <BaseCompensationFilingOrgAmt>260723</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>67855</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>2544</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>28378</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>359500</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>CATHERINE WEBER</PersonNm>
        <TitleTxt>VP DEVELOPMENT OPERATIONS</TitleTxt>
        <BaseCompensationFilingOrgAmt>164629</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>31200</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>6782</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>23622</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>226233</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>STEPHANIE H ELSEA</PersonNm>
        <TitleTxt>VP MARKETING &amp; COMMUNICATIONS</TitleTxt>
        <BaseCompensationFilingOrgAmt>169428</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>17500</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>828</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>7000</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>11812</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>206568</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>ANDREW S RAKEMAN</PersonNm>
        <TitleTxt>VICE PRESIDENT OF RESEARCH</TitleTxt>
        <BaseCompensationFilingOrgAmt>150095</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>8063</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>333</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>6285</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>25894</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>190670</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART I, LINE 4A</FormAndLineReferenceDesc>
        <ExplanationTxt>SEVERANCE COMPENSATION SCHEDULE J, PART I, LINE 4A ROBERT F. VIZZA RECEIVED SEVERANCE COMPENSATION OF $315,180 IN CALENDAR YEAR 2020. NONFIXED PAYMENTS SCHEDULE J, PART I, LINE 7 IN 2020, OFFICERS AND EMPLOYEES RECEIVED NONFIXED DISCRETIONARY BONUSES AS REPORTED ON SCHEDULE J, PART II, COLUMN (B)(II).</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleJ>
    <IRS990ScheduleM documentId="RetDoc1042900001">
      <SecuritiesPubliclyTradedGrp>
        <NonCashCheckboxInd>X</NonCashCheckboxInd>
        <ContributionCnt>33</ContributionCnt>
        <NoncashContributionsRptF990Amt>142960</NoncashContributionsRptF990Amt>
        <MethodOfDeterminingRevenuesTxt>AVG MKT VALUE</MethodOfDeterminingRevenuesTxt>
      </SecuritiesPubliclyTradedGrp>
      <AnyPropertyThatMustBeHeldInd>0</AnyPropertyThatMustBeHeldInd>
      <ReviewProcessUnusualNCGiftsInd>1</ReviewProcessUnusualNCGiftsInd>
      <ThirdPartiesUsedInd>0</ThirdPartiesUsedInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SCHEDULE M, PART I, COLUMN (B)</FormAndLineReferenceDesc>
        <ExplanationTxt>THE AMOUNT IN COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleM>
    <IRS990ScheduleO documentId="RetDoc1044400001">
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART III, LINE 4A</FormAndLineReferenceDesc>
        <ExplanationTxt>THE FOUNDATION'S MISSION IS TO CURE PANCREATIC CANCER. TO ADVANCE PROGRESS TOWARD THIS GOAL, THE FOUNDATION COMMITTED AN ADDITIONAL $24 MILLION TO RESEARCH DURING FY2021, BRINGING THE CUMULATIVE TOTAL INVESTED THROUGH JUNE 2021 TO $225 MILLION. BECAUSE RESEARCH IS FUNDAMENTAL AND PROGRESS IS PARAMOUNT, THE FOUNDATION HAS SUPPORTED MORE THAN 300 PROJECTS WORLDWIDE, WITH PARTNERSHIPS AT NEARLY 70 ACADEMIC INSTITUTIONS. ADDITIONALLY, THE FOUNDATION PROVIDES TWO-THIRDS OF THE WORLD'S PRIVATE FUNDING FOR PANCREATIC CANCER RESEARCH FROM ORGANIZATIONS FOCUSED SOLELY ON THIS DISEASE. DURING FY2021, MAJOR LUSTGARTEN-FUNDED RESEARCH MILESTONES AND ACHIEVEMENTS HAVE FOCUSED ON: STRETCHING THE BOUNDARIES OF SCIENCE THROUGH CLINICAL TRIALS: THE FOUNDATION ESTABLISHED THE CLINICAL ACCELERATOR INITIATIVE (CAI) TO SHORTEN THE TIME FROM CLINICAL TRIAL CONCEPT TO LAUNCH USING A LUSTGARTEN-DEVELOPED PROCESS BASED ON THE BEST AVAILABLE SCIENCE AND EMPLOYING CUTTING-EDGE BIOMARKERS. THESE "SMARTER" CLINICAL TRIALS WILL GENERATE LARGE VOLUMES OF DATA THAT SCIENTISTS CAN USE NOW AND, IN THE FUTURE, TO INFORM AND IMPROVE CLINICAL TRIALS AND EXPEDITE NEW TREATMENTS. IN 2021, THE FOUNDATION APPROVED $6.1 MILLION TO FUND FOUR CAI STUDIES. THREE OF THESE CLINICAL STUDIES TEST IMMUNOTHERAPY TREATMENTS - LOOKING INTO WAYS THE BODY'S OWN IMMUNE SYSTEM CAN WORK TO COMBAT PANCREATIC CANCER SO MORE PATIENTS HAVE BETTER OUTCOMES. TWO STUDIES, ONE FOR METASTATIC PATIENTS AND ONE FOR PATIENTS IN THE NEOADJUVANT (PRE-SURGERY) SETTING, EXAMINE NEW COMBINATIONS OF VACCINES AND DRUGS TARGETING THE IMMUNE SYSTEM TO DETERMINE IF THEY CAN PREVENT TUMORS FROM BECOMING RESISTANT TO IMMUNE THERAPIES. THE THIRD STUDY TESTS A NEW COMBINATION OF DRUGS TO SIMULTANEOUSLY ACTIVATE THE T CELLS AND BLOCK THE INHIBITORY SIGNALS FROM THE TUMOR. THE TRANSLATIONAL ADVISORY GROUP, LED BY CHIEF MEDICAL ADVISOR DR. ELIZABETH JAFFEE AND COMPRISED OF RENOWNED PANCREATIC CANCER EXPERTS, GUIDES THE CAI BY IDENTIFYING, REVIEWING AND DEVELOPING THE BEST TRANSLATIONAL PROJECTS TO IMPACT PATIENT CARE IN THE CLINIC. THE TRANSLATIONAL ADVISORY GROUP IS BUILDING A NETWORK OF SITES TO EXECUTE THE PROPOSED RESEARCH IN SMALL CLINICAL TRIALS OF 10-20 PATIENTS EACH. THESE SCIENCE-DRIVEN STUDIES COULD DRAMATICALLY INFORM RESEARCH, ENABLING INVESTIGATORS TO QUICKLY DETERMINE IF PATIENTS ARE RESPONDING TO SPECIFIC TREATMENT APPROACHES AND WHY - INFORMATION THAT WILL HELP ENHANCE CLINICAL TRIALS AND ULTIMATELY, CLINICAL CARE. ACCELERATING THE PACE OF DISCOVERY AT THE DEDICATED LUSTGARTEN LABS: THE LUSTGARTEN FOUNDATION IS THE ONLY NON-PROFIT TO FUND FIVE DEDICATED PANCREATIC CANCER RESEARCH LABS. THESE LABS ARE UNITED IN THEIR SHARED GOALS OF INCREASING COLLABORATION BETWEEN WORLD-RENOWNED PANCREATIC CANCER RESEARCHERS, EXPLORING PROMISING AVENUES FOR UNDERSTANDING AND TREATING PANCREATIC CANCER AND IMPROVING PATIENT OUTCOMES. - COLD SPRING HARBOR LABORATORY (LONG ISLAND, NEW YORK) FOCUSING ON PERSONALIZED MEDICINE DR. DAVID TUVESON LEADS THE LUSTGARTEN LABORATORY AT COLD SPRING HARBOR LABORATORY, DESIGNING NEW MODELS OF THE DISEASE AND DISCOVERING NOVEL THERAPEUTIC AND DIAGNOSTIC PLATFORMS TO BRING NEW OPTIONS TO PATIENTS MORE RAPIDLY. DR. TUVESON WAS THE FIRST SCIENTIST TO DEVELOP A PANCREATIC CANCER ORGANOID - A THREE-DIMENSIONAL CELL CULTURE SYSTEM WHICH REPRODUCES A PATIENT'S TUMOR. THIS ENABLES RESEARCHERS TO REPEATEDLY TEST THE EFFECTIVENESS OF DIFFERENT DRUGS TO ACCURATELY PREDICT HOW A PATIENT WILL RESPOND TO VARIOUS THERAPIES, OFFERING THE HOPE OF PERSONALIZED CANCER TREATMENTS. IN ADDITION TO OTHER PROJECTS, THE LAB'S ORGANOID FACILITY IS GROWING AND TESTING ORGANOIDS FOR THE ONGOING PASS-01 CLINICAL TRIAL. - DANA-FARBER CANCER INSTITUTE (BOSTON, MASSACHUSETTS) ADVANCING TRANSLATIONAL RESEARCH UNDER THE LEADERSHIP OF DR. BRIAN WOLPIN, THE LUSTGARTEN LABORATORY AT DANA-FARBER IS A CRITICAL HUB FOR ADVANCING RESEARCH FROM THE LABORATORY TO THE CLINIC, INITIATING SCIENTIFICALLY-DRIVEN CLINICAL TRIALS AND IDENTIFYING NEW APPROACHES TO EARLY DETECTION. DR. WOLPIN AND HIS TEAM ARE ALSO ANALYZING PANCREATIC CANCER SUBTYPES TO UNDERSTAND MECHANISMS OF DRUG RESISTANCE AND THE GENETIC DRIVERS THAT DETERMINE EACH SUBTYPE. DURING FY2021, DR. WOLPIN AND HIS TEAM BEGAN STUDYING A POTENTIAL PROCESS TO "RE-AWAKEN" T CELLS (AN IMMUNE SYSTEM CELL) THAT PENETRATE THE PANCREATIC TUMORS BUT ARE RENDERED "EXHAUSTED AND INEFFECTIVE BY TUMOR SIGNALS. THE CLINICAL STUDY WILL TEST A NEW COMBINATION OF DRUGS DESIGNED TO SIMULTANEOUSLY ACTIVATE THE T CELLS AND BLOCK THE INHIBITORY SIGNALS FROM THE TUMOR. - JOHNS HOPKINS (BALTIMORE, MARYLAND) FURTHERING EARLY DETECTION AND THERAPEUTICS DIRECTED BY DR. BERT VOGELSTEIN, THE LUSTGARTEN LABORATORY AT JOHNS HOPKINS IS USING ITS EXPERTISE IN EARLY DETECTION TO DISCOVER PANCREATIC CANCER AT AN EARLIER STAGE, WHEN PATIENTS MAY BE SURGICAL CANDIDATES, AND IS DEVELOPING NEW THERAPEUTIC APPROACHES BASED ON GENETIC ALTERATIONS. IN 2021, EXACT SCIENCES ACQUIRED THE RIGHTS TO CANCERSEEK, A POWERFUL BLOOD TEST CAPABLE OF DETECTING THE EARLY PRESENCE OF MULTIPLE CANCERS AND DEVELOPED AT THE JOHNS HOPKINS LAB. (PLEASE SEE EARLY DETECTION SECTION WITHIN THIS DOCUMENT FOR MORE INFORMATION ON EARLY DETECTION ADVANCEMENTS.) - JOHNS HOPKINS (BALTIMORE, MARYLAND) ADVANCING IMMUNOLOGY LED BY DR. ELIZABETH JAFFEE, THIS LAB IS WORKING TO BRING NOVEL THERAPIES FOR PANCREATIC CANCER TO THE CLINIC AS QUICKLY AS POSSIBLE. BUILDING ON DECADES OF EXPERIENCE AND EXPERTISE IN THE IMMUNOLOGY OF PANCREATIC CANCER, DR. JAFFEE AND HER TEAM ARE FOCUSING ON IMMUNE THERAPIES AND DEVELOPING APPROACHES TO BRING THE BENEFITS OF THIS REVOLUTIONARY APPROACH TO TREATING TUMORS TO PANCREATIC CANCER. - MASSACHUSETTS INSTITUTE OF TECHNOLOGY (CAMBRIDGE, MASSACHUSETTS) MERGING TECHNOLOGY AND ENGINEERING THE LUSTGARTEN LABORATORY AT MIT IS LEVERAGING ITS UNPARALLELED EXPERTISE IN CANCER BIOLOGY AND ENGINEERING TO ADVANCE PANCREATIC CANCER RESEARCH. LED BY DR. TYLER JACKS, THE LABORATORY IS STUDYING THE GENETIC EVENTS CONTRIBUTING TO CANCER DEVELOPMENT AND EXAMINING THE IMMUNE RESPONSES TO THE DISEASE USING MOLECULAR PROFILING TO IDENTIFY TUMOR MUTATIONS. DR. JACKS AND HIS TEAM ALSO ARE RUNNING PRECLINICAL TRIALS IN MOUSE MODEL SYSTEMS TO SEE WHICH DRUGS AND DRUG COMBINATIONS WORK BEST TO BRING ABOUT A PROPER IMMUNE RESPONSE AGAINST PANCREATIC CANCER. PURSUING EARLY DETECTION TECHNIQUES: - CANCERSEEK ACCELERATES EARLY DETECTION LUSTGARTEN-FUNDED RESEARCH AT JOHNS HOPKINS PLAYED AN INSTRUMENTAL ROLE IN THE DEVELOPMENT OF AN EARLY DETECTION BLOOD-BASED TEST CALLED CANCERSEEK THAT CAN IDENTIFY THE PRESENCE OF MULTIPLE CANCERS. A 2020 LANDMARK STUDY, DEMONSTRATED CANCERSEEK SHOWED PROMISING RESULTS FOR EARLIER DETECTION AS PART OF ROUTINE MEDICAL CHECKS, ENABLING POTENTIALLY CURATIVE TREATMENT THAT COULD CHANGE PATIENT OUTCOMES. THE STUDY FOUND THAT THE TEST MORE THAN DOUBLED THE NUMBER OF CANCERS THAT WERE FIRST "SCREEN-DETECTED AND IDENTIFIED UNDIAGNOSED CANCERS IN 10 DIFFERENT ORGANS (INCLUDING SEVEN WITH NO CURRENT STANDARD-OF-CARE SCREENING). EXACT SCIENCE, WHICH ACQUIRED THE RIGHTS TO CANCERSEEK IN 2021, IS PREPARING TO INITIATE AN 80,000-PERSON REGISTRATION TRIAL AS A STEP TOWARD ACHIEVING FDA APPROVAL. - ARTIFICIAL INTELLIGENCE IS KEY TO DETECTING PANCREATIC CANCER EARLIER LUSTGARTEN-FUNDED RESEARCHERS AT JOHNS HOPKINS ALSO ARE USING ARTIFICIAL INTELLIGENCE TO DETECT PANCREATIC CANCER EARLIER. THROUGH THEIR RESEARCH, THEY'VE TRAINED COMPUTERS TO RECOGNIZE PATTERNS IN MEDICAL IMAGES TO DETECT PANCREATIC TUMORS ON CT SCANS AND IDENTIFY TUMORS MEASURING ONE CENTIMETER OR LESS, WHEN THEY MAY BE MISSED BY A DIAGNOSTICIAN, SO DIAGNOSIS AND SUBSEQUENT TREATMENT CAN BE STARTED MUCH SOONER. - COMPCYST TEST CAN PREVENT UNNECESSARY SURGERIES THE LUSTGARTEN-DEDICATED LABORATORY AT JOHNS HOPKINS IS DEVELOPING A TEST CALLED COMPCYST, WHICH COMBINES CLINICAL, RADIOLOGICAL, GENETIC AND PROTEIN MARKER INFORMATION TO CLASSIFY PANCREATIC CYSTS AND DETERMINE WHICH ONES REQUIRE SURGERY. THE LUSTGARTEN LABORATORY AT JOHNS HOPKINS IS WORKING TO FURTHER DEVELOP COMPCYST INTO A CLINICALLY APPROVED TEST.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART III, LINE 4A</FormAndLineReferenceDesc>
        <ExplanationTxt>IDENTIFYING NOVEL THERAPEUTIC APPROACHES: THE FOUNDATION'S THERAPEUTICS-FOCUSED RESEARCH PROGRAM WAS CREATED TO ENSURE A ROBUST AND FLOURISHING PIPELINE OF POTENTIAL TREATMENTS AND TO ENABLE COLLABORATION. TO DATE, THE THERAPEUTICS-FOCUSED RESEARCH PROGRAM HAS AWARDED 11 GRANTS TOTALING MORE THAN $12.3 MILLION. FUNDED PROJECTS ADDRESS FOUR KEY AREAS OF PANCREATIC CANCER BIOLOGY: - LEARNING HOW THE STROMA - THE SUPPORTIVE TISSUE SURROUNDING THE PANCREATIC TUMOR - MAY HELP PROTECT TUMORS FROM THE IMMUNE SYSTEM AND RESIST THERAPIES. - UNDERSTANDING AND DISCOVERING HOW TO BLOCK THE INFLAMMATORY SIGNALS THAT CAN LEAD TO PANCREATIC CANCER AND OTHER PANCREATIC DISEASES IN RESPONSE TO ENVIRONMENTAL CAUSES. - DETERMINING WAYS TO STOP TUMOR CELL GROWTH BY BLOCKING THE ABNORMAL METABOLIC PATHWAYS USED BY PANCREATIC CANCER CELLS. - PREVENTING THE SPREAD - OR METASTASIS - OF CANCER BY ISOLATING METASTATIC TRIGGERS IN CANCER CELLS AND THE STROMA. EXPANDING COLLABORATION WITH STAND UP TO CANCER: THE PANCREATIC CANCER COLLECTIVE (PCC), A JOINT INITIATIVE OF THE LUSTGARTEN FOUNDATION AND STAND UP TO CANCER, IS MAKING GROUNDBREAKING PROGRESS IN IDENTIFYING NEW WAYS TO TREAT PANCREATIC CANCER AND IMPROVING OUTCOMES FOR PATIENTS. THE COLLECTIVE HAS SUPPORTED RESEARCH LED BY MORE THAN 400 RESEARCH INVESTIGATORS AT APPROXIMATELY 70 PARTICIPATING INSTITUTIONS INCLUDING NEARLY 30 CLINICAL TRIALS. WORK BEGAN ON FOUR PROJECTS SUPPORTED THROUGH THE PCC'S "NEW THERAPIES CHALLENGE GRANTS." APPROVED FOR SECOND-ROUND FUNDING IN FY20, THESE POTENTIAL TREATMENTS BEGAN CLINICAL TRIALS IN FY21. IN FY21, THE COLLECTIVE PROVIDED NEW FUNDING FOR TWO ADDITIONAL IMMUNOTHERAPY CLINICAL TRIALS AS PART OF DR. ELIZABETH JAFFEE'S "CONVERGENCE DREAM TEAM TRANSLATIONAL RESEARCH GRANT": - $900,000 TO SUPPORT A STUDY LED BY PHIL GREENBERG, MD, FRED HUTCHINSON CANCER CENTER TO INVESTIGATE EFFICACY OF A TARGETED T-CELL RECEPTOR MEDIATED CELLULAR THERAPY TARGETING THE MESOTHELIN PROTEIN TO ELIMINATE PANCREATIC AND OVARIAN CANCER. - $422,854 TO SUPPORT A STUDY LED BY ROBERT D. SCHREIBER, MD, WASHINGTON UNIVERSITY, TO EXPLORE THE SAFETY AND IMMUNOTHERAPEUTIC POTENTIAL OF ADMINISTRATION OF PERSONALIZED NEOANTIGEN VACCINES TO PATIENTS WITH PANCREAS CANCER. THE PANCREATIC CANCER COLLECTIVE (PCC), A JOINT INITIATIVE OF THE LUSTGARTEN FOUNDATION AND STAND UP TO CANCER, IS MAKING GROUNDBREAKING PROGRESS IN IDENTIFYING NEW WAYS TO TREAT PANCREATIC CANCER AND IMPROVING OUTCOMES FOR PATIENTS. THE COLLECTIVE CONTINUES CONDUCTING NEARLY 30 CLINICAL TRIALS LED BY MORE THAN 400 RESEARCH INVESTIGATORS AT APPROXIMATELY 70 PARTICIPATING INSTITUTIONS. ADDRESSING EQUITY, DIVERSITY AND INCLUSION IN PANCREATIC CANCER RESEARCH: SOLVING THE COMPLEX PROBLEM OF PANCREATIC CANCER REQUIRES DIVERSITY OF THOUGHT, EDUCATION, TRAINING, BACKGROUND AND EXPERIENCE TO MOVE PROGRESS FORWARD. OUR COMMITMENT TO ENSURING EQUITY, DIVERSITY AND INCLUSION - ACROSS LUSTGARTEN-FUNDED RESEARCH AND THE SCIENTISTS WE SUPPORT - IS FOUNDATIONAL TO OUR MISSION TO CURE PANCREATIC CANCER. SUPPORTING DISTINGUISHED EARLY-CAREER SCIENTISTS HELPS ENSURE THEIR CONTINUED COMMITMENT TO STUDYING PANCREATIC CANCER. THE LUSTGARTEN FOUNDATION CREATED TWO CAREER DEVELOPMENT AWARDS TO INCREASE THE NUMBER OF EARLY-CAREER WOMEN AND UNDERREPRESENTED SCIENTISTS RECEIVING FUNDING FOR PANCREATIC CANCER RESEARCH. THE AWARDS SUPPORT INVESTIGATORS COMMITTED TO INCREASING OUR UNDERSTANDING AND TREATMENT OF THIS DISEASE. THE AWARDS HONOR THE LIVES AND LEGACIES OF TWO TRAILBLAZING AMERICANS LOST TO PANCREATIC CANCER - JUSTICE RUTH BADER GINSBURG AND CONGRESSMAN JOHN ROBERT LEWIS. EACH RECIPIENT IS AWARDED A THREE-YEAR, $300,000 GRANT FOR THEIR PANCREATIC CANCER RESEARCH. - CAREER DEVELOPMENT AWARD IN HONOR OF RUTH BADER GINSBURG WAS AWARDED TO DANNIELLE ENGLE, PHD, AN ASSISTANT PROFESSOR AT THE SALK INSTITUTE FOR BIOLOGICAL STUDIES. DR. ENGLE IS INVESTIGATING THE ROLE OF PANCREATITIS AND INFLAMMATION IN THE FORMATION OF PANCREATIC CANCER. - CAREER DEVELOPMENT AWARD IN HONOR OF JOHN ROBERT LEWIS WAS AWARDED TO AVERY D. POSEY JR., PHD, AND ASSISTANT PROFESSOR IN THE PERELMAN SCHOOL OF MEDICINE AT THE UNIVERSITY OF PENNSYLVANIA. DR. POSEY IS CONTINUING HIS RESEARCH TO INCREASE IMMUNE SYSTEM EFFECTIVENESS AT ATTACKING PANCREATIC CANCER. IN ADDITION, DR. POSEY WAS INVITED TO PRESENT AT THE INAUGURAL JUNETEENTH LUSTGARTENLIVE! WEBINAR.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION A, LINE 2</FormAndLineReferenceDesc>
        <ExplanationTxt>CHARLES F. DOLAN, JAMES L. DOLAN AND QUENTIN DOLAN - FAMILY AND BUSINESS RELATIONSHIP. MARCIA LUSTGARTEN, ANDREW LUSTGARTEN AND JESSICA LUSTGARTEN COURTEMANCHE - FAMILY RELATIONSHIP.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 11B</FormAndLineReferenceDesc>
        <ExplanationTxt>FORM 990 IS REVIEWED BY THE PRESIDENT FOR ACCURACY AND REASONABLENESS PRIOR TO SUBMISSION TO THE IRS. ADDITIONALLY A COMPLETE COPY OF THE FINAL RETURN IS PROVIDED TO ALL VOTING BOARD MEMBERS PRIOR TO FILING WITH THE IRS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 12C</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ORGANIZATION HAS A WRITTEN CONFLICT OF INTEREST POLICY. THE WRITTEN POLICY REQUIRES ANNUAL DISCLOSURES BY ALL MEMBERS OF THE BOARD OF DIRECTORS, OFFICERS, AND KEY PERSONS OF ANY INTEREST THAT COULD GIVE RISE TO CONFLICT. THE ORGANIZATION REGULARLY AND CONSISTENTLY MONITORS AND ENFORCES THE COMPLIANCE OF THE CONFLICT OF INTEREST POLICY. IN THE INSTANCE WHERE A DIRECTOR HAS A CONFLICT, THEY ARE ASKED BY THE BOARD CHAIR TO RECUSE THEMSELVES FROM DELIBERATIONS, DECISIONS AND THE VOTE.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 15</FormAndLineReferenceDesc>
        <ExplanationTxt>COMPENSATION FOR THE CHIEF EXECUTIVE OFFICER AND THE PRESIDENT WAS REVIEWED AND APPROVED BY THE INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS IN 2021. THE REVIEW WAS UNDERTAKEN BY A THIRD-PARTY HUMAN RESOURCES CONSULTANT AND INCLUDED THE USE OF COMPARABILITY DATA WHICH WAS CONTEMPORANEOUSLY DOCUMENTED.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION C, LINE 19</FormAndLineReferenceDesc>
        <ExplanationTxt>AUDITED FINANCIAL STATEMENTS ARE MADE AVAILABLE ON THE ORGANIZATION'S WEBSITE. IN ADDITION, GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND AUDITED FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleO>
  </ReturnData>
</Return>
